Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 2/20 | 0.32 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22598242 | 0.93 | GAA (0.38) | GAAMAPTMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL22327226 | 0.93 | GAA (0.38) | GAAMAPTMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL22598257 | 0.93 | GAA (0.38) | GAAMAPTMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL25753951 | 0.92 | GAA (0.37) | GAAMAPTMAOBALDH1A1KMT2A | |
| SCHEMBL26167728 | 0.92 | GAA (0.36) | GAAMAPTMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL22598364 | 0.88 | ALDH1A1 (0.35) | GAAMAPTMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL26167737 | 0.88 | SMN1; SMN2 (0.35) | MAOBSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL22327371 | 0.88 | ALDH1A1 (0.35) | GAAMAPTMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL22327071 | 0.88 | ALDH1A1 (0.35) | GAAMAPTMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL22327329 | 0.88 | GAA (0.38) | GAAMAPTMAOBSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | NUDT1, RNMT, ADAR | GAA 668/4885MAPT 4693/4885MAOB 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.